Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Toll-like receptor 8 is a protein encoded by the TLR8 gene. It acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. The Toll Like Receptor 8 (CD288 or TLR8) Development market research report provides an in-depth analysis of Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects.

Mechanisms of Action of Toll Like Receptor 8 Pipeline Market

The mechanisms of action of the Toll Like Receptor 8 pipeline market are Toll Like Receptor 8 Agonist and Toll Like Receptor 8 Antagonist.

Toll Like Receptor 8 pipeline market, by mechanisms of action

Toll Like Receptor 8 pipeline market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in Toll Like Receptor 8 Pipeline Market

The routes of administration in the Toll Like Receptor 8 pipeline market are oral, subcutaneous, intratumor, intravenous, intravesical, topical, intradermal, intramuscular, intrathecal, nasal, and parenteral.

Toll Like Receptor 8 pipeline market, by routes of administration

Toll Like Receptor 8 pipeline market, by routes of administration

For more routes of administration insights, download a free report sample

Molecule Types in Toll Like Receptor 8 Pipeline Market

The molecule types in the Toll Like Receptor 8 pipeline market are small molecule, monoclonal antibody conjugated, fusion protein, monoclonal antibody, mRNA vaccine, subunit vaccine, and synthetic peptide.

Toll Like Receptor 8 pipeline market, by molecule types

Toll Like Receptor 8 pipeline market, by molecule types

For more molecule type insights, download a free report sample

Key Toll Like Receptor 8 Pipeline Market Companies

Some of the key companies in the Toll Like Receptor 8 pipeline market are Silverback Therapeutics Inc, Altimmune Inc, Ambrx Biopharma Inc, Ascendis Pharma AS, Avidea Technologies Inc, Bolt Biotherapeutics Inc, Bristol-Myers Squibb Co, Curebiotech Inc, Curevac NV, Dynavax Technologies Corp, and Eisai Co Ltd.

Toll Like Receptor 8 pipeline market, by companies

Toll Like Receptor 8 pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Mechanisms of Action Toll Like Receptor 8 Agonist and Toll Like Receptor 8 Antagonist
Routes of Administration Oral, Subcutaneous, Intratumor, Intravenous, Intravesical, Topical, Intradermal, Intramuscular, Intrathecal, Nasal, and Parenteral
Molecule Types Small Molecule, Monoclonal Antibody Conjugated, Fusion Protein, Monoclonal Antibody, mRNA Vaccine, Subunit Vaccine, and Synthetic Peptide
Key Companies Silverback Therapeutics Inc, Altimmune Inc, Ambrx Biopharma Inc, Ascendis Pharma AS, Avidea Technologies Inc, Bolt Biotherapeutics Inc, Bristol-Myers Squibb Co, Curebiotech Inc, Curevac NV, Dynavax Technologies Corp, and Eisai Co Ltd

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Toll Like Receptor 8 (CD288 or TLR8).
  • Reviews of Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in Toll Like Receptor 8 (CD288 or TLR8) therapeutics and enlists all their major and minor projects.
  • Assessment of Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • Summaries of all the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Toll Like Receptor 8 (CD288 or TLR8).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8).
  • Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Altimmune Inc
Ambrx Biopharma Inc
Ascendis Pharma AS
Avidea Technologies Inc
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
Curebiotech Inc
Curevac NV
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
IngenoVax LLC
Janus Biotherapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Merck KGaA
Nektar Therapeutics
Novartis AG
Resolve Therapeutics LLC
Seven and Eight Biopharmaceuticals Corp
Seven and Eight Biopharmaceuticals Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Zhimeng Biopharma Inc
Silverback Therapeutics Inc
UroGen Pharma Ltd
Vaccex Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 8 (CD288 or TLR8) – Overview

Toll Like Receptor 8 (CD288 or TLR8) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 8 (CD288 or TLR8) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 8 (CD288 or TLR8) – Companies Involved in Therapeutics Development

Altimmune Inc

Ambrx Biopharma Inc

Ascendis Pharma AS

Avidea Technologies Inc

Bolt Biotherapeutics Inc

Bristol-Myers Squibb Co

Curebiotech Inc

Curevac NV

Dynavax Technologies Corp

Eisai Co Ltd

Galderma SA

Gilead Sciences Inc

IngenoVax LLC

Janus Biotherapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

Merck KGaA

Nektar Therapeutics

Novartis AG

Resolve Therapeutics LLC

Seven and Eight Biopharmaceuticals Corp

Seven and Eight Biopharmaceuticals Inc

Shanghai De Novo Pharmatech Co Ltd

Shanghai Zhimeng Biopharma Inc

Silverback Therapeutics Inc

UroGen Pharma Ltd

Vaccex Inc

Toll Like Receptor 8 (CD288 or TLR8) – Drug Profiles

afimetoran – Drug Profile

Product Description

Mechanism Of Action

History of Events

ALT-702 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BDB-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BDB-018 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BDB-030 – Drug Profile

Product Description

Mechanism Of Action

BDB-102 – Drug Profile

Product Description

Mechanism Of Action

BDC-1001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CB06-036 – Drug Profile

Product Description

Mechanism Of Action

CUCPT-8m – Drug Profile

Product Description

Mechanism Of Action

CV-8102 – Drug Profile

Product Description

Mechanism Of Action

History of Events

DN-1508052 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs to Agonize TLR8 for Fibrosis and Solid Tumors – Drug Profile

Product Description

Mechanism Of Action

E-6742 – Drug Profile

Product Description

Mechanism Of Action

History of Events

enpatoran – Drug Profile

Product Description

Mechanism Of Action

History of Events

HRS-9950 – Drug Profile

Product Description

Mechanism Of Action

imiquimod – Drug Profile

Product Description

Mechanism Of Action

History of Events

imiquimod + zalifrelimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

INGMM-1 – Drug Profile

Product Description

Mechanism Of Action

JB-6121 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody Conjugates to Agonize TLR 7 and 8 for Unspecified Cancer – Drug Profile

Product Description

Mechanism Of Action

motolimod – Drug Profile

Product Description

Mechanism Of Action

History of Events

NKTR-262 – Drug Profile

Product Description

Mechanism Of Action

History of Events

resiquimod – Drug Profile

Product Description

Mechanism Of Action

History of Events

resiquimod – Drug Profile

Product Description

Mechanism Of Action

History of Events

resiquimod SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

RSLV-132 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SBT-6050 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SBT-6290 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SBT-8230 – Drug Profile

Product Description

Mechanism Of Action

History of Events

selgantolimod – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Agonize TLR7 and TLR8 for Solid Tumors – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize TLR7 and TLR8 for Autoimmune Disorders – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Antagonize TLR8 for Rheumatoid Arthritis – Drug Profile

Product Description

Mechanism Of Action

History of Events

SYN-001 – Drug Profile

Product Description

Mechanism Of Action

VTX-1463 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Toll Like Receptor 8 (CD288 or TLR8) – Dormant Products

Toll Like Receptor 8 (CD288 or TLR8) – Discontinued Products

Toll Like Receptor 8 (CD288 or TLR8) – Product Development Milestones

Featured News & Press Releases

Jan 06, 2022: Bolt Biotherapeutics doses first patient with BDC-1001 in combination with OPDIVO (nivolumab) in ongoing phase 1/2 clinical trial for the Treatment of HER2-expressing solid tumors

Dec 14, 2021: Ascendis Pharma virtual R&D program update highlights continued development across R&D pipeline

Dec 07, 2021: Ascendis Pharma to host virtual R&D program update on December 14

Dec 06, 2021: Bolt Biotherapeutics reports interim BDC-1001 phase 1/2 data demonstrating a safe and well-tolerated profile and emerging clinical activity at the ESMO Immuno-Oncology Congress 2021

Dec 02, 2021: Bolt Biotherapeutics to present interim clinical data on BDC-1001 phase 1/2 clinical trial at ESMO Immuno-Oncology Congress 2021

Nov 13, 2021: Seven and Eight Biopharma’s BDB001 in combination with an anti-PD-L1 mAb shows favorable safety and clinical responses in interim phase 1 data presented at the 2021 SITC Annual Meeting

Nov 12, 2021: Silverback Therapeutics presents preclinical data for SBT8230 at AASLD The Liver Meeting 2021

Nov 12, 2021: Silverback Therapeutics presents SBT6050-201 trial in progress poster at Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Nov 10, 2021: CureVac presents promising data at SITC from Phase 1 study of oncology candidate CV8102 showing systemic immune response

Nov 09, 2021: Ascendis Pharma presents new non-clinical data for TransCon TLR7/8 agonist oncology program at SITC 2021

Sep 16, 2021: Silverback Therapeutics presents interim clinical results from the ongoing phase 1/1b study of SBT6050 alone or in combination with Pembrolizumab in patients with advanced or metastatic HER2-expressing solid tumors

Sep 13, 2021: Silverback Therapeutics to present data from its phase 1/1b clinical trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress

Sep 07, 2021: Seven and Eight Biopharmaceuticals announces the first patient treated in a phase 2 clinical trial of the TLR 7/8 dual agonist BDB001 in anti-PD-1 / anti-PD-L1 refractory solid tumors

Jun 24, 2021: Resolve Therapeutics to start Phase II Trial of RSLV-132 for long Covid

Jun 23, 2021: Seven and Eight Biopharmaceuticals announces the first patient treated in a first-in-human clinical trial of the TLR7/8 dual agonist BDB018 in advanced solid tumors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Indications, 2022 (Contd..3)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Altimmune Inc, 2022

Pipeline by Ambrx Biopharma Inc, 2022

Pipeline by Ascendis Pharma AS, 2022

Pipeline by Avidea Technologies Inc, 2022

Pipeline by Bolt Biotherapeutics Inc, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Curebiotech Inc, 2022

Pipeline by Curevac NV, 2022

Pipeline by Dynavax Technologies Corp, 2022

Pipeline by Eisai Co Ltd, 2022

Pipeline by Galderma SA, 2022

Pipeline by Gilead Sciences Inc, 2022

Pipeline by IngenoVax LLC, 2022

Pipeline by Janus Biotherapeutics Inc, 2022

Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Pipeline by Merck KGaA, 2022

Pipeline by Nektar Therapeutics, 2022

Pipeline by Novartis AG, 2022

Pipeline by Resolve Therapeutics LLC, 2022

Pipeline by Seven and Eight Biopharmaceuticals Corp, 2022

Pipeline by Seven and Eight Biopharmaceuticals Inc, 2022

Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022

Pipeline by Shanghai Zhimeng Biopharma Inc, 2022

Pipeline by Silverback Therapeutics Inc, 2022

Pipeline by UroGen Pharma Ltd, 2022

Pipeline by Vaccex Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.